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SUMMARY 
 
   This study had two aims: 
1) to assess the tumour size at metastatic dissemination by analyzing the relationship between tumor 
diameter and incidence of distant metastases during the 25 years after initial treatment, 
2) to investigate the impact of a residual tumor on the probability of distant dissemination. 
   An analysis of the data registered at the Institut Gustave Roussy in Villejuif was undertaken on about 
4000 breast cancer patients treated prior to the use of adjuvant chemotherapy and followed-up 
for over 15 years.  
   The data show that the volume at which dissemination occurs in 50% of patients can be estimated 
in each subset of patients as defined by the size of the tumour, histopathologic grade and number 
of involved axillary nodes. This V50 varies widely but is inversely correlated with the histologic grade 
and the number of involved axillary nodes. Moreover, a gradual increase in the grade of the tumours 
was observed during their growth, confirming the usefulness of early treatment and breast screening. 
   The analysis of the delay between the initial treatment and clinical emergence of the metastases 
shows that the excess of distant metastases in patients with local recurrence corresponds 
to disseminations which are initiated after initial treatment, and therefore originated from the residual 
tumor. This finding emphasizes the importance of loco-regional treatment.  
   Whereas during the first 2 years after treatment the incidence of distant metastases was lower 
in the arm treated by chemotherapy (P=0.32, NS), from the third year on, the reverse was observed 
and the incidence of metastases was significantly lower in the group treated by post-op RT + poly 
A – poly U (P<10-4). At 15 years, the incidence was significantly lower in the group treated by post-op 
RT + poly A – poly U (42% metastasis-free survival in the RT group and 29% in the CT group p=0.03). 
This result seems to be due mostly to lower incidence of local recurrence. But even in patients without 
local recurrence, the incidence of distant metastasis is not greater than that in patients treated 
by CMF, which might be due to the favourable effect of poly A – poly U. The results of this trial are 
consistent with those of other recent clinical trials, and emphasize the favourable impact of post-op RT 
and the paramount importance of local control on the long-term outcome of the disease. 
 
INTRODUCTION 
 
   It was shown a few decades ago that 
post-operative radiotherapy (post-op RT) 
markedly reduced the incidence of local 
recurrence both after a mastectomy and 
as a conservative surgery; subsequently 
several controlled clinical trials reported 
a higher survival in patients having 
received post-op RT. Nevertheless, 
the usefulness of post-op RT in routine 
clinical practice is still controversial. 
The first reason is that the data are 
somewhat conflicting. The discrepancies 
appear to be mostly related to the quality 
of radiation therapy. In the first studies, 
the dose was often not sufficient to control 
residual disease [1,2,3,4], or the treatment 
duration was too long [5]. In order to pre-
vent local recurrence, a sufficient dose 
of 40-50 Gy in 4-5 weeks has to be delive-
red [3,4]. After lower doses or longer pro-
traction, the incidence of local recurrence 
is appreciable [3]. Moreover, the toxicity
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of RT is far from being negligible when 
the doses to the heart, the great vessels 
or the lungs are high [6]. Thus the signify-
cance of the first meta-analysis was li-
mited because trials with poor or satis-
factory radiation techniques and doses 
were pooled together [7]. Since it is di-
fficult retrospectively to discard trials with 
unsatisfactory techniques (such as ortho-
voltages) only recent trials should be con-
sidered.  
   Secondly, the methodology of the sta-
tistical studies was often debatable. A five 
year follow-up is much too short to allow 
any conclusions to be drawn as we will 
show below. Moreover, statistical studies, 
in which only the first site of recurrence 
is monitored, are misleading: in patients 
submitted to post-op RT local recurrences 
are suppressed or delayed, consequently, 
the frequency of distant metastases, 
as the first site of recurrence, is arte-
factually increased [8]. Similarly, in pa-
tients who did not receive RT, the high 
incidence of locoregional recurrence 
conceals the actual frequency of distant 
metastases. 
   Thirdly, the interpretation of the data 
must take into account the natural history 
of breast cancer. For example, the growth 
rate of breast cancer is slower in older 
patients [9] (Table 1), therefore the delay 
between treatment and recurrence is lon-
ger, which may explain the difference 
between pre and postmenopausal 
patients. Similarly, the growth rate of histo-
pathologic grade 1 tumors is slower, 
and the delay TM (time interval between 
initial treatment and detection of metasta-
ses) between treatment and recurrence, 
as well as the overall metastatic growth 
duration are longer (Table 1). In general, 
in patients with good prognostic indicators, 
such as the absence of nodal involvement, 
the delay is longer and therefore a longer 
follow-up is required to evidence the be-
neficial effect of post-op RT.  
 
 
Table 1. The median growth duration (GD) is the time interval between the first proliferation of the first metastatic cell 
and the clinical detection of the metastasis. It was calculated in each subset of patients with the method previously described 
(8). GD is equal to the sum of IT (the part of the metastatic growth that has occurred before the treatment of the tumor) and TM 
(the time interval between initial treatment and detection of the metastases). IT is calculated and TM measured. TM values are 
given in parentheses after the GD value. GD is approximately equal to 20 doubling times (DT) (12). Therefore the mean DT 
appears to be about 3 months. The values indicated in parenthesis are the theoretical cumulated proportions of patients with 
distant metastases after a very long delay since treatment (23). The growth durations were computed assuming in (A) that 
metastases in excess were initiated before initial treatment and in (B) that they originated from residual tumor after initial 
treatment. As discussed in this paper, A values are not consistent with our knowledge of tumor cell kinetics, therefore 
in the table the values given are those calculated with the latter hypothesis. 
 
 
 
Median metastatic growth duration 
in months 
Proportion of pts with met at 20 y 
Groups of patients in pts without LR  in pts with LR pts without LR pts with LR 
Overall population 67  45 0.45 0.86 
Age £ 40 58  42 0.51 0.78 
41 - 60 65  44 0.46 0.88 
 60 69  48 0.41 0.85 
Tumor diameter      
0 – 3.9 cm 112  71 0.31 0.79 
4 – 5.9 cm 71  72 0.47 0.86 
> 6 cm 49  33 0.68 0.93 
Nodal involvement      
0 100  67 0.22 0.70 
     (¥ 0.75) 
1 - 3 103  71 0.43 0.85 
> 4 71  48 0.64 0.95 
Histol. Grade  A B   
I 115 641 157 0.22 0.66 
     (¥ 0.85) 
II 94  61 0.47 0.88 
III 55  33 0.49 0.90 
Based on data from reference 8. 
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   This paper has two aims: the first one 
is to review our knowledge on the natural 
history of breast cancer and the link 
between local recurrence and distant 
dissemination, and the second one is 
to interpret the clinical results in the light 
of this knowledge. 
  Natural history of human breast cancer: 
Until recently, the description of the natural 
history of human cancers had remained 
purely qualitative. However, with the intro-
duction of computerized cancer registries, 
we are now able to extract reliable 
quantitative information that otherwise 
could not have been obtained from 
the huge amount of data found in patient 
files [10,11,12,13,14,15,16]. 
   The main event during the growth 
of a human tumour is metastatic dissemi-
nation [17]. Prior to its occurrence, 
the breast cancer is a locoregional disease 
which is easily cured by local treatment. 
The tumor size at metastatic dissemination 
varies widely [10,15]. Dissemination has 
already occurred in some breast cancers 
of less than 5 mm in diameter, whereas 
it has not occurred in some bulky tumors 
of more than 8 cm in diameter cured by 
local treatment alone.  
   A major goal of the study of the natural 
history of breast cancer is the analysis 
of the relationship between tumor size and 
the probability of metastatic dissemination 
as well as the influence on this relationship 
of the various tumor characteristics, such 
as the histologic grade and the number 
of involved axillary nodes [15]. In 1975, 
we undertook a study which was based 
on the analysis of the data registered 
at the Institut Gustave-Roussy in Villejuif 
on over 3000 breast cancer patients 
treated prior to the use of adjuvant 
chemotherapy, their follow-up ranging 
from 15 to 32 years [10]. The data showed 
that the proportion of distant metastases 
appearing more than 25 years after 
treatment is negligible. In patients without 
local recurrence, the cumulative proportion 
of patients with distant metastases after 
25 years of follow-up can therefore 
be assumed to be equal to the probability 
of distant dissemination before initial 
treatment. We subdivided the population 
of patients into eight classes according 
to tumor volume and the tumour diameter 
at surgery, and plotted for each class 
the actuarial cumulated proportion of pa-
tients with metastases as a function 
of time after treatment up to 25 years. The 
patients with distant metastasis at initial 
work-up were included in this cumulated 
proportion. The relationship between 
the volume at the time of diagnosis and 
the cumulative proportion of patients with 
distant metastases is sigmoid. The distri-
bution of tumor size at initiation is log 
normal. For tumors larger than 1 cm 
in diameter, a small decrease in the size 
of the tumor at initial treatment results 
in a marked reduction in the proportion 
of patients with occult metastases. This is 
the rationale behind screening procedures 
[10]. 
   Moreover, it was found that the average 
threshold volume at which dissemination 
occurs is inversely correlated with 
the number of involved lymph nodes [13] 
and the histologic grade of the tumor [15]. 
In order to quantify the influence of histo-
logic grade on the probability of metastatic 
dissemination for tumors of all sizes, 
the patients were subdivided into three 
groups according to the histologic grade. 
In each subgroup, there was a significant 
correlation between tumor size and 
the probability of distant spread, but 
the median tumor size at dissemination 
was markedly larger for grade 1 tumors 
[15] (Table 2). An interesting observation 
made during the study was that the pro-
portion of grade 1 tumors was higher 
in small tumors than in large ones, while 
the reverse was observed for grade 3 tu-
mors; these data suggest that, during their 
growth, tumors progress towards higher 
grades [15]. Table 5 shows that for a dia-
meter of 0.35 cm half of the tumors have 
already a grade higher than 1. This pro-
gnosis of the grade was later confirmed 
by the Tabar et al. data [18]. The gradual 
increase in a tumor’s malignant potential 
concurs with the concept of tumor 
progression, which postulates that tumors 
evolve from “bad to worse” [19]. 
   Another finding was that the proportion 
of patients without lymph node invol-
vement diminishes rapidly as a function 
of tumor size, while the proportion of pa-
tients with four or more involved nodes 
increases markedly. These observations 
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are consistent with a model assuming 
the existence of a threshold volume for no-
dal invasion and gradual axillary node 
involvement during tumor growth [13]. 
The data support a model in which there 
is an orderly pattern of nodal involvement 
from no lymph node involvement to invol-
vement of one lymph node and subse-
quently of two lymph nodes and so on. 
The data strongly suggest that tumors with 
early first node involvement are also those 
which invade the second and the third 
node early. Each tumor progresses at its 
own pace. The propensity for lymph node 
involvement varies from tumor to tumor. 
However, the data correspond to a uni-
modal distribution of the tumors, from 
those with a high propensity and the ear-
liest nodal involvement to those with 
the lowest and the latest involvement. 
These data are in clear contradiction 
to the model of Slack et al. [20], which 
assumed the existence of two subgroups 
of breast tumors, those with high and tho-
se with low propensity. It is possible to 
estimate the tumor diameter for which 
50% of tumors have initiated distant 
metastases in patients with various 
histological grades and numbers of invol-
ved axillary lymph nodes (Table 3). 
 
Table 2. Median tumor diameter (cm) at the time 
of the involvement of the first axillary node and at initiation 
of distant metastases, and median delay TM (months) 
between treatment and emergence of the first metastasis. 
(from ref. 10, 12, 13). 
 
Grade 
Lymph node 
involvement 
Distant 
metastases 
Delay TM 
treatment -
- emergence 
of the first met
1 2.8 4.8 65 months 
2 1.27 2.8 44 months 
3 0.89 2.4 21 months 
 
Table 3. Tumor diameter (cm) for which 50 % of tumors 
have initiated distant metastases as a function of the histo-
logic tumor grade, and number of involved nodes (from 
ref. 10). 
 
 Number of involved axillary nodes 
 0 1 - 3 4 - 10 > 10 
Grade 1 9 4.8 3.1 2.5 
Grade 2 or 3 3.7 2.6 2 1.8 
   Once the size of the tumor at initiation 
of distant metastasis and at invasion 
of the first lymph node had been estimated 
it was possible to show that there was 
a strong and highly significant correlation 
between these two sizes in the various 
subsets of patients, and therefore to cal-
culate for a tumor of a given size the pro-
bability of distant dissemination as a fun-
ction of histologic grade and number of in-
volved axillary lymph nodes (Table 4). 
 
Table 4. Proportion of patients with distant metastases 
as a function of diameter of the tumor, the histopatologic 
grade (Gr), and the number (N) of involved axillary nodes. 
(from ref. 15). 
 
Tumor Diameter 
1 cm 2 cm 4 cm 
N Gr 1 2 + 3 Gr 1 2 + 3 Gr 1 2 + 3 
0 - 4 12 8 19 16 35 
1 - 3 11 36 17 44 35 58 
4 - 9 16 51 24 59 45 68 
 10 19 68 29 67 59 79 
 
   The data also show that, during tumor 
progression, the capacity for lymphatic 
spread is on average acquired much 
earlier than the capacity for hematogenous 
spread [15] (Table 5). Thus, the assump-
tion that all patients with involved axillary 
nodes are at high risk of distant metastasis 
is overly pessimistic. Knowing the tumor 
diameter, the grade and the number of in-
volved axillary nodes of a patient, it beco-
mes possible to estimate the probability 
of distant spread (Table 4). 
   Tumor volumes at the invasion of the 
first axillary node are approximately 1.5 ti-
mes larger in patients with a tumor located 
in the inner quadrants than in those with 
tumors located in the outer quadrants 
and patients with outer quadrant tumors 
have earlier axillary node invasion (Table 6). 
Nevertheless, for tumors located in the in-
ner or the outer quadrants, the median 
size at first metastatic dissemination is not 
statistically different in the two subgroups, 
and, if anything, is slightly smaller 
for the inner quadrant tumors [13]. 
This discrepancy shows that the corre-
lation between node involvement and dis-
tant spread is not causal. Distant dissemi-
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nation is not a two-step process. Axillary 
involvement is a good index of the pro-
pensity of tumor cells to acquire the cap-
acity for hematogenous spread, but it is not 
the cause of this spread.  
 
Table 5. Tumor size and prognostic factors. 
 
 Tumor diameter 
1. Grade 1  Grade > 1 0.35 cm 
2. Grade < 3  Grade 3 7 cm 
3. Axillary lymph node 1.3 cm 
                             0  1  
4. Internal mammary chain 3.9 cm 
                             0  1  
                     (inner quadrants)  
5. Distant metastases  
     (pts without local recurrence) 3.8 cm 
      7   MO  MA  
 
The mean diameter of the tumor for which in 50 % of pa-
tients: 
1. the histological grade becomes greater than 1 
2. the histological grade becomes equal to 3 
3. the first axillary lymph node is involved 
4. the first internal mammary chain lymph node is invol-
ved for patients with breast tumor located in the inner 
quadrant 
5. distant dissemination occurred. 
(compiled from ref. 8, 13, 15) 
 
 
Table 6. Median tumor diameter (cm) at the time of first 
and second axillary node involvement and at metastatic 
dissemination in inner and outer quadrant tumors. (from 
ref. 8 and 13). 
 
 All pts Inner Quadrants 
Outer 
Quadrants 
Involvement 
of first 
axillary node 
   
0  1 1.32 1.36 1.15 
Involvement 
of second 
axillary node 
   
0  2 2.86 3.11 2.76 
Metastatic 
dissemination 
 
2.87 
 
2.60 
 
3.0 
 
   Locoregional recurrence rates are much 
higher in patients with nodal involvement 
and are correlated with the number of in-
vaded nodes [4]. Lymphatic spread is the-
refore also a pointer of local tumor cell 
migration and invasion of the surrounding 
tissues.  
Hence the studies of the cell kinetics 
of breast cancer and those of its natural 
history lead to several practical con-
clusions: 
1 – The delay TM between the initial 
treatment and the clinical emergence 
of occult metastases depends on (a) 
The growth rates (i.e. their doubling 
time) of the metastases and of the pri-
mary tumor, (b) The size of the primary 
tumor at which distant dissemination 
occurred. (This critical size is smaller 
in tumors of high grade and/or with 
nodal involvement) and, (c) There 
is a strong correlation between 
the growth rate of distant metastases 
and the time interval between detection 
of metastases and death [9,15,21,22]. 
The growth rate of the primary tumor 
or its DNA labelling index are very 
strong independent prognostic factors, 
a high proliferatie rate being asso-
ciated with a high probability of early 
distant dissemination [15,21]. 
2 – Early involvement of axillary lymph 
nodes is strongly correlated with early 
distant spread and with rapid growth 
rate of the tumor and its metastasis. 
However, despite this correlation, 
growth rate and early lymph node 
involvement have an independent and 
highly significant prognostic value [15]. 
3 – The growth rate of breast cancer 
is relatively slow, the mean tumor 
doubling time is about 9 months. 
The mean doubling time of metastases 
is much shorter, about 4 months. Both 
vary markedly and metastatic growth 
duration (GD) are shorter in patients 
under 40 and slightly longer in patients 
over 60 years (Table 1). They are also 
much shorter in patients with high 
grade tumors or nodal involvement. 
   The growth rate of tumor metastasis can 
be estimated in the various subsets 
of patients by analyzing the delay TM 
between initial treatment and clinical 
emergence of the metastasis [8]. The me-
dian metastasis growth duration (GD) 
is equal to IT (time interval between 
the initiation of metastases and treatment 
of the primary tumor) plus TM. TM can 
be measured and IT is evaluated in each 
subset of patients if the mean size 
of the primary tumor at the time of initial 
treatment and the primary tumor growth 
rate are known. The size at metastatic 
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initiation can be assessed if the histologic 
grade and the number of involved lymph 
nodes are known. The accuracy of the eva-
luation of the growth duration of the meta-
stases can be improved by searching 
the best fit with the metastasis appearance 
curve [8]. GD is about equal to 20 doubling 
times. The value evaluated for GD corres-
ponds to a mean doubling time of a few 
months (3 to 4 months), which is con-
sistent with the doubling time measured 
on sequential chest X-rays of patients with 
lung metastases [23,24]. The results 
of these evaluations confirm the influence 
of the grade, the nodal involvement, and 
the age on the metastatic growth rate 
(Table 1). They also show that the meta-
stases detected after treatment of large 
tumors have a more rapid growth rate [8], 
which is consistent with the concept 
of tumor progression [19], illustrated 
by the progression from hormone 
dependence to independence [25] and 
the progression of histologic grade [15,18]. 
 
The link between local recurrence 
and distant dissemination 
 
   Numerous data show that there is also 
a strong correlation between the existence 
of residual disease after initial treatment 
and distant dissemination [26,27,28,29,30, 
31,32,33,34,35,36]. Two possible explana-
tions have been proposed for the incre-
ased incidence of distant metastases 
observed in patients with locoregional 
recurrences (LR). Either LR is the signa-
ture of tumor aggressiveness, and then 
avoiding recurrences (i.e., by radiothe-
rapy) is of little value. The alternative 
is that LR is a nidus for metastatic 
dissemination. In order to investigate this 
problem, four thousand patients cones-
cutively treated in the same institution from 
1954 to 1975 were studied [8]. None 
of them had received adjuvant chemo-
therapy. Tumor characteristics, local 
recurrence, and first detection of distant 
metastases had been prospectively 
registered for each patient and mean 
values were calculated in the various 
subsets of patients.  
   The proportion of metastasis-free 
patients was lower by about 80% in all 
subsets of patients with LR (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In patients without LR, the monthly rate 
of distant metastases incidence decreases 
continuously with time after initial treat-
ment. Conversely, in patients with local 
recurrence, this rate increases during the 
first year after initial treatment, and the 
metastases in excess appear slightly later 
than in patients without local recurrence. 
Using a mathematical model, it can be 
shown that, in patients with local 
recurrence, nearly all of the metastases 
in excess had been initiated after initial 
treatment [8]. The assumption that even 
in patients with local recurrence the meta-
stases in excess were initiated from 
the primary tumor is not plausible because 
if this were the case the growth of the me-
tastases would have to be much slower 
than that of the metastases initiated from 
the tumors of patients without local 
recurrence. On the other hand it is known 
that the most malignant tumors have 
0.95
0.90
0.80
0.70
0.50
0.30
0.20
0.10
0.05
0.02
10 100 1000
After 20 years
follow-up
At diagnosis
Fig. 1. Relationship between clinical tumor volume
(log-scale) and proportions of metastases at long-term 
(probit scale). Each symbol corresponds to a group
of patients: circles to groups of LR- patients, and squares
to LR+. Groups are defined at 1 cm step in diameter. 
Patients with metastases are not excluded. The lower curve 
displays the relationship between tumor volume and pro-
portion of patients with synchronous metastases. The slo-
pes of the curve corresponding to metastases detected 
during the follow-up of LR- patients and of the lower curve 
are equal. In LR+ patients, there is no significant correlation 
between tumor size and proportion of patients with 
metastases, and the curve is not parallel to the curve 
corresponding to propoptions of patient with synchronous 
metastases. The regression lines were calculated after 
pooling data concerning LR+ and LR- patients.
(from ref. 8).
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a more rapid growth rate [17,21,22,23]. 
Moreover, if the metastases had a slower 
growth rate, the time interval between 
emergence of the metastases and death 
would be longer [23], which is not what 
was observed [8]. Hence our results are 
at variance with the hypothesis that 
a greater tumor aggressiveness in patients 
with LR explains the excess of meta-
stases. Therefore, it can be concluded that 
most of the metastases in excess 
observed in patients with local recurrence 
originated after initial surgery from 
the residual tumor [8].  
   Metastatic growth duration was esti-
mated in each subset of patients (Table 1). 
Patients with local recurrence have shorter 
growth duration. This is in keeping with 
the well known clinical observation: local 
recurrence occurs preferentially in patients 
with the most malignant tumors.  
   Furthermore, the lack of any relationship 
between tumor size and cumulative 
proportion of metastases in patients with 
local recurrence is consistent with the hy-
pothesis that residual tumor is the nidus 
for distant spread [8]. As shown in Table 2, 
among patients with LR the long-term 
proportion of patients with metastases 
is often equal to 80% - 90%. Even 
in the most favourable subset of patients 
it is superior to 75%. This is in contrast 
with grade 1 patients without local recurre-
nce in whom the cumulated proportion 
plateaus around 25% after a follow-up 
of 20 years. These data emphasize that 
the prognosis of tumors becomes 
dramatically worse when a locoregional 
recurrence occurs. However, the delays 
between initial treatment and clinical 
detection of metastases can be very long 
in patients with local recurrence. Among 
patients with favourable prognostic factors: 
the superior limit of the 95% confidence 
interval can be as long as 30 years 
in grade 1 tumors. These data underline 
the need for a very long follow-up in pa-
tients with local recurrences and show 
also the fallacy of conclusions based on 
a follow-up of less than 10 years, in par-
ticular for patients with breast cancers 
of good prognosis.  
   RT can prevent distant metastasis only 
by controlling the residual tumor which 
could be a nidus for distant spread. RT, 
therefore, can be beneficial only in pa-
tients without occult distant metastases 
at the time of initial treatment, and with 
a residual tumor after surgery [26]. Thus, 
accurate estimation of the likelihood of dis-
tant spread in each subset of patients 
is a prerequisite for identifying the subset 
of patients for whom more effective local 
treatment could improve the outcome. 
In patients with poor prognostic factors, 
the proportion of patients without occult 
metastases is small. Conversely, in pa-
tients with good prognostic factors, 
the proportion of patients with a residual 
tumor after surgery is small. Thus the be-
neficial effect of RT is likely to be small 
and, therefore, difficult to evidence [26].  
   Post-op RT can control residual tumors, 
but it has no impact on the growth rate 
of metastases. On the other hand, adju-
vant chemotherapy reduces the number 
of viable cells in metastasis at each ad-
ministration, and therefore, slows down 
their growth rate during the treatment 
period. It can be expected that it increases 
the time interval between initial treatment 
and clinical detection of the metastasis 
and reduces the rate of emergence 
of distant metastases during the first few 
years after treatment. 
 
DISCUSSION OF THE CLINICAL DATA 
 
   This knowledge of breast tumor natural 
history and of the impact of treatment 
on the growth rate of occult metastases 
facilitates the interpretation of clinical data. 
In the first controlled trial comparing 
conservative treatment and mastectomy 
by Atkins [1], the incidence of distant 
metastases was higher in stage II patients 
treated by conservative surgery + radio-
therapy than in those treated by mastec-
tomy. This appears to be the consequence 
of a too low radiation dose which was 
unable to control residual tumor. Later 
it was shown in several controlled trials 
that when a dose of 50 Gy was delivered 
after conservative surgery with a proper 
fractionation and protraction there was 
no difference in overall survival between 
conservative treatment and radical 
mastectomy [37,38,39,40]. 
   Several controlled trials have compared 
patients with or without post-op RT after 
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surgery [29,41]. Meta-analyses of these 
trials have been carried out [7,42,43]. 
In the 1995 overview of 35 randomized 
trials of surgery and RT (including 28,465 
women for whom data on mortality was 
available) there was no survival advantage 
of the irradiated over the non-irradiated 
group after mastectomy or breast 
conserving surgery [42]. RT reduced death 
from breast cancer but was associated 
with an increased risk of death from other 
causes. However, as discussed in the in-
troduction, no analysis was made in this 
study of the radiation dose and the te-
chnique of RT, whereas both these factors 
are likely to have a strong impact 
on the therapeutic results. In the subse-
quent meta-analysis published in 2000 
by the Oxford Group [43], there is a small 
benefit: the mortality caused by the cancer 
is reduced; however this advantage is 
partly offset by an increase in cardio-
vascular mortality. The better results 
of post-op RT in the recent meta-analysis 
are probably due to the inclusion of more 
recent trials, in which the radiation 
technique was better. It is also due 
to a longer follow-up since, as discussed 
above, the favourable consequences 
of the control of residual tumor are ob-
served after relatively long follow-ups 
(over 7 or 8 years). This is why the excess 
of distant metastases attributable to the re-
sidual tumor is easily overlooked at a fol-
low-up of only five years. Indeed our data 
show that only about half of the distant 
dissemination in excess in patients with 
local recurrence are detected during 
the first five years of follow-up [8]. 
This proportion is smaller in patients with 
good prognostic factors (histologic grade 
I or absence of nodal involvement). 
   However, it should be recognized that 
there is a wide discrepancy between 
the spectacular reduction in the incidence 
of local-regional recurrence and the small 
decrease in cancer mortality. In 1986, 
we already discussed this point and sho-
wed that, as discussed above, post-op RT 
can avoid distant dissemination only in pa-
tients without occult metastases at initial 
treatment and with residual tumor, which 
will cause local recurrence when post-op 
RT is not performed [26]. In 1986, we es-
timated that only 15% to 20% of the pa-
tients belonged to this category. This pro-
portion is probably not much greater 
today, which is why the potential gain 
is limited. However, even if not very large, 
this gain compares favourably with that 
associated with adjuvant chemotherapy 
and does not compete with it. 
 
RESULTS OF A RECENT CLINICAL 
TRIAL COMPARING CHEMOTHERAPY 
AND POST-OP RT 
 
   It is relevant, in this context, to discuss 
the results of a French Federation of Can-
cer Centers (FFCC) controlled trial re-
cently updated at the Institut Gustave 
Roussy [44] and which, in 500 patients 
with stage II and III breast cancer with 
involved axillary nodes treated by mastec-
tomy, compared two adjuvant treatments: 
chemotherapy with CMF versus post-op 
RT associated with immunotherapy 
by poly A-poly U. The incidence of local 
recurrence was identical in the two arms 
during the first two years. Thereafter there 
were only few recurrences in the RT-AU 
arm. At 15 years follow-up, the cumulative 
incidence of local recurrence was 18% 
(CI95 13-24) in the post-op AU arm and 
45% (CI 38-53) in the CMF arm. This 40% 
reduction is highly significant (p<10-6). 
Thus despite the reduction in local 
recurrence induced by chemotherapy [45], 
the reduction in post-op RT appears much 
greater despite the fact that in this multi-
center trial the RT technique was probably 
not optimal, as shown by the relatively 
high incidence of local recurrence 
in the RT arm. Among operable patients 
with tumors of the inner quadrants and 
with involved internal mammary chain, 
the model predicts that over one third 
of them have no distant metastases. 
This result as we have emphasized 
[26,28,41] is consistent with the effect-
tiveness of the treatment of the internal 
mammary chain.  
   The annual incidence of distant 
metastases was lower in the CMF arm 
during the first two years, and the diffe-
rence was statistically significant (log rank). 
However, from the third year till the fif-
teenth, (Fig. 2) it became lower in the RTAU 
arm, and the difference is highly signi-
ficant. At 15 years follow-up, the cumu-
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lative incidence is 43% (CI95 50-37) 
in the RTAU arm and 29% (CI 36-23) 
in the CMF arm (p=0.04) (Fig. 5). The ove-
rall survival (OS) was nearly identical 
in the two arms till the seventh year 
of the follow-up. From the ninth year, 
it became slightly higher in the RTAU arm, 
but the difference is not statistically 
significant. At the ten - year follow-up 
the OS is 55% (CI 48-61) in the RTAU arm 
and 48% (CI 40-54) in the CMF arm and 
at 15 years follow-up they are respectively 
43% (CI 36-50) and 36% (CI 30-42). 
The relative risk of death in the RT poly 
AU arm, as compared with the CMF arm, 
is RR=0.87. There was no difference 
in the time interval between the clinical 
emergence of distant metastases and 
death between the two arms of the trial, 
which shows that among patients with 
distant metastases the growth rate and 
aggressiveness of the disease were 
comparable in the two arms [8,23]. A com-
parison of the metastases-free survival 
arm as a function of its histological grade 
[46], is of interest. In patients with grade 
1 tumors, there is no difference in the pro-
portion of metastases at 5 years whereas 
at 15 years follow-up there is a clear 
difference (Fig. 3). In patients with grade 
3 tumors, the two curves diverge after 
the second year, and are parallel from the 
fifth till the fifteenth year of the follow-up 
(Fig. 4). The data concerning grade 2 tu-
mors are intermediary. These curves are 
consistent with what is known regarding 
the slow growth rate of grade 1 tumors, 
and the rapid growth of grade 3 tumors [8,9]. 
   The FFCC trial was stopped prematurely 
because the incidence of local recurrence 
was identical in the two arms during 
the first two years; moreover the prelimi-
nary data suggested that CMF might give 
a lower incidence of distant metastases. 
In fact, after a longer follow-up there 
is a reduction in the incidence of distant 
metastases by nearly one third, which 
is greater than the gain observed 
in the trials where post-op (RT) is added 
to systemic therapy. Unfortunately, the num-
ber of patients included in the trial com-
paring CMF versus post-op RT + poly AU 
was not sufficient to make detailed 
comparisons. Nevertheless, it allows seve-
ral remarks: [1] The long-term incidence 
of distant metastases is significantly lower 
in pa-tients treated by RT+AU than in pa-
tients treated by CMF. In this pragmatic 
trial it is difficult to distinguish the role 
of post-op RT and that of immunotherapy. 
Nevertheless, we have attempted to esti-
mate the respective impact of the two 
treatment modalities. The first method that 
we used was to censor patients with local 
recurrence at the time of the detection 
of the first distant metastases (Fig. 5). 
With this method, the metastases that 
could have been initiated in the residual 
tumor are ignored, and the metastases 
which are taken into account are mostly 
those which originated from the primary 
tumor. In this case the metastases-free 
survival rates are similar, which suggests 
that the effectiveness of CMF and poly AU 
is analogous [2] Another method is to in-
troduce a correction factor (Fig. 6). 
Our previous study enabled us to evaluate 
the excess incidence of distant meta-
stases which are associated with local 
recurrence. If we introduce these data 
in a simulation model the benefit arising 
from a lower incidence of local recurrence 
can be excluded and it becomes possible 
to assess the independent role of immu-
notherapy. Indeed the curves of meta-
stases-free survival, when corrected 
for the metastases associated with local 
recurrences, also suggest that the efficacy 
of CMF is not greater than that of poly A 
– poly U. This conclusion is consistent with 
the results of the previous controlled trial 
comparing patients with breast cancer 
receiving poly A – poly U as an adjuvant 
immunotherapy to with those not receiving 
it [47,48]. If this conclusion is correct 
the difference between the two groups 
in the incidence of distant metastases can 
be attributed to post-op RT. This result 
is in accordance with the results of recent 
trials assessing the impact of post-op RT 
in patients receiving adjuvant chemo-
therapy to be discussed below. 
   Another study, the second Stockholm 
trial [29,49], compared, CMF versus post-
op RT in 1020 patients with breast cancer. 
The incidence of local recurrence was 
markedly reduced in patients receiving 
post-op RT, and the analysis 
of cumulated recurrence demonstrated 
a  strong  correlation  between  the  loco- 
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Fig. 2. Proportion of metastasis-free patients studied
by Kaplan Meier. During the first two years, the incidence
of metastatic dissemination is lower in the chemotherapy 
arm. However, from the third to the fifteenth, the incidence 
becomes lower in the radiotherapy + poly AU arm. At 15y, 
the cumulative incidence is 43% (CI 50-37) in RTAU arm
and 29% (CI 36-23) in the CMF arm.  
 
 
 
 
 
Log Rank test value:      p=1.76 0.18
79 39 32 11
72 28 20 7
Histological grade (SBR)=3
Log Rank test value: 1.76 p=0.18
Treatment
Poly-AU + RTCMF
Proportion
0.0
0.2
0.4
0.6
0.8
1.0
Years since initial treatment
0 5 10 15
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the third year the incidence of distant metastasis is lower
in the RT + poly AU arm, the difference is smaller and 
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Fig. 3. Proportion of metastasis-free patients in the group 
with histological grade 1.
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Fig. 5. In order to eliminate the impact of local recurrence
on the incidence of distant dissemination, patients are 
censored at the time of local recurrence. The difference 
between the two arms after the third year disappears.  
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regional control and subsequent distant 
metastases. Thus the data are consistent 
with the above results of the FFCC trial. 
Unfortunately, in the Stockholm trial, only 
the first site of recurrence was monitored, 
therefore a detailed comparison with 
the FFCC trial is difficult.  
   RT acts by controlling the residual 
tissue, and thereby suppressing the nidus 
for further dissemination. The aim of adju-
vant chemotherapy is to destroy distant 
micro metastases. An analysis with a si-
mulation mathematical model of the meta-
stasis appearance curve in treated and 
in control patients has shown that 
the maximum number of cells in the occult 
metastases controlled by the chemo-
therapy is approximately 106 [50]. 
Assuming that the proportion of clonogenic 
cells is 10-3, it follows that the proportion 
of surviving tumor cells after completion 
of 6 cycles of CMF is 10-3 [50]. This cor-
responds to a radiation dose equal 
to 10D50 (approximately 25 Gy) delivered 
to the whole body in six sessions. Thus 
adjuvant chemotherapy and postoperative 
RT do not compete but are comple-
mentary. Indeed, the most recent trials 
have compared in patients treated by sur-
gery and adjuvant systemic therapy 
(chemotherapy or tamoxifen) those with 
or without post-op RT [51,52]. The meta-
analysis which has been carried out 
in the eighteen trials identified (involving 
6367 patients), has shown a strong re-
duction in local recurrence, improved re-
lapse-free survival and overall survival, 
confirming the results of these three trials 
[53]. Some authors have hypothesized 
that this favourable effect is observed 
because adjuvant systemic therapy allo-
wed locoregional radiation to manifest its 
effect [53]. Rather the above discussion 
suggests that the beneficial effect has 
become significant because 1) the trials 
are more recent and, therefore, the irra-
diation technique of adequate quality and, 
2) the follow-up is longer. 
   In these studies, adding post-op RT 
to classical systemic therapy did not raise 
any ethical problems and is readily acce-
pted, whereas it was clear in the FFCC 
trial that many oncologists were reluctant 
to withhold systemic adjuvant therapy 
in patients who could benefit from it. 
   Moreover, the statistical study of Fortin 
et al. [54] concurs with ours [8] in demon-
strating the causal responsibility of local 
failure in the death of a significant pro-
portion of patients.  
   The role of immunological factors 
in breast cancer is another topic which 
remains controversial. In the 1970s, some 
authors [55] described the depression 
of immunological defenses caused by ra-
diotherapy and the alleged increase of dis-
tant spread in some patients treated 
by radiotherapy. Later, doubts have arisen 
regarding the efficacy of immunotherapy 
despite it’s positive effect observed in our 
previous trial [47,48]. The FFCC study 
brings new data to this debate [44], and 
justifies the opportunity to carry out new 
controlled clinical trials to assess the res-
pective benefit of post-op RT and 
immunotherapy.  
   Most trials assessing the benefits 
of post-operative radiotherapy have 
included node positive patients; it would 
be of interest to undertake studies on node 
negative patients. In this context, the pro-
blem discussed in the current literature 
is whether post-op RT is merited in pa-
tients with good prognostic factors and 
high probability of cure without post-op RT 
[45,56,57,58]. Our data show that although 
local recurrences are more frequent in pa-
tients with poor prognostic factors, the in-
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cidence remains relatively high even 
in the best subset of patients. A. Wallgren 
[57] has recently argued that in patients 
with small tumors only 6% of them will 
experience local relapse after a 5 - year 
follow-up. Our data lead us to expect that 
this proportion will increase up to 10 
to 12% at a 10 - year follow-up, and that 
70% of patients with local recurrence will 
experience distant metastases. The delay 
between initial treatment, emergence 
of distant metastases and death, might be 
long (ten to twenty-five years) but never-
theless this sequence of events is likely 
to be observed [8]. Thus the benefit 
of post-op RT should be of about 7% 
to 8%, a gain which should not be over-
looked since it corresponds to about 
a quarter of the overall mortality in this 
type of breast cancer. However, this po-
tential gain might be offset by the long-
term toxicity of radiation if the irradiation 
technique is not optimal.  
   The rationale behind post-operative RT 
after mastectomy or tumorectomy is cu-
rrently well documented [26,29,31,33,43, 
54,58,59,60]. Here again the main ques-
tion is, therefore, the cost of the potential 
gain in terms of radiation toxicity on lung, 
heart and the great vessels, and to what 
extent this toxicity can be reduced or avo-
ided by advances in radiation techniques. 
The analysis of cardiac toxicity has shown 
that the toxicity is much greater in patients 
with large volumes of the heart irradiated 
with relatively high doses (in particular 
in patients with tumors located in the left 
breast) [6,61]. As recently discussed in se-
veral papers [6,62,63], we can reasonably 
expect that with electrons, multileaf colli-
mators and conformal RT or intensity 
modulated RT, the dose to the heart and 
the great vessels can be dramatically dimi-
nished, thereby minimizing vascular and 
cardiac morbidity. This would eliminate 
the main reason for denying the benefit 
of post-op RT to low risk patients. 
   The last question is whether RT or sy-
stemic treatment should come first. In prin-
ciple, it would be logical to start with RT, 
and this was the conclusion of a retro-
spective study [64]. This conclusion was 
challenged by a controlled trial carried out 
on 244 patients [65]. However, our data 
show that the follow-up was much too 
short to draw any conclusions. Another 
possibility could be interdigitated treat-
ment, which may decrease the toxic risk, 
but this is a complex technique. 
   In conclusion, the analysis of the ava-
ilable data shows that there is a causal 
relationship between the lack of local con-
trol of the primary tumor and the increase 
in the incidence of distant metastases 
in patients with local failure. Post-operative 
radiation therapy is therefore justified, but 
the dose should be sufficient and the ra-
diotherapy technique should aim at mini-
mizing the dose to the heart and the great 
vessels, which is now possible thanks 
to the modern methods of radiotherapy. 
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